Realcan Pharmaceutical Group Co., Ltd. (002589.SZ)
CNY 2.95
(4.24%)
CNY 2.95
(4.24%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.11 Billion CNY | 17.24% |
| 2022 | 954.51 Million CNY | -53.84% |
| 2021 | 2.06 Billion CNY | -29.6% |
| 2020 | 2.93 Billion CNY | -19.47% |
| 2019 | 3.64 Billion CNY | -18.98% |
| 2018 | 4.5 Billion CNY | 13.13% |
| 2017 | 3.97 Billion CNY | 133.1% |
| 2016 | 1.7 Billion CNY | 66.49% |
| 2015 | 1.02 Billion CNY | 44.3% |
| 2014 | 710.58 Million CNY | 38.42% |
| 2013 | 513.35 Million CNY | 33.1% |
| 2012 | 385.69 Million CNY | 28.2% |
| 2011 | 300.84 Million CNY | 57.09% |
| 2010 | 191.51 Million CNY | 52.63% |
| 2009 | 125.47 Million CNY | 16.23% |
| 2008 | 107.95 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 978.04 Million CNY | -12.6% |
| 2024 Q2 | 926.47 Million CNY | -5.27% |
| 2024 Q3 | 892.32 Million CNY | -3.69% |
| 2023 Q3 | 788.33 Million CNY | -10.08% |
| 2023 FY | 1.11 Billion CNY | 17.24% |
| 2023 Q4 | 1.11 Billion CNY | 41.95% |
| 2023 Q2 | 876.69 Million CNY | 13.99% |
| 2023 Q1 | 769.07 Million CNY | -19.43% |
| 2022 Q1 | 1.88 Billion CNY | -8.84% |
| 2022 FY | 954.51 Million CNY | -53.84% |
| 2022 Q4 | 954.51 Million CNY | -32.05% |
| 2022 Q3 | 1.4 Billion CNY | -17.9% |
| 2022 Q2 | 1.71 Billion CNY | -9.23% |
| 2021 FY | 2.06 Billion CNY | -29.6% |
| 2021 Q4 | 2.06 Billion CNY | -4.94% |
| 2021 Q2 | 2.4 Billion CNY | -9.26% |
| 2021 Q3 | 2.17 Billion CNY | -9.66% |
| 2021 Q1 | 2.65 Billion CNY | -9.66% |
| 2020 Q3 | 3.02 Billion CNY | -2.13% |
| 2020 FY | 2.93 Billion CNY | -19.47% |
| 2020 Q1 | 3.57 Billion CNY | -1.92% |
| 2020 Q2 | 3.08 Billion CNY | -13.73% |
| 2020 Q4 | 2.93 Billion CNY | -2.76% |
| 2019 Q2 | 4.11 Billion CNY | -0.71% |
| 2019 Q4 | 3.64 Billion CNY | -7.15% |
| 2019 Q3 | 3.92 Billion CNY | -4.49% |
| 2019 FY | 3.64 Billion CNY | -18.98% |
| 2019 Q1 | 4.14 Billion CNY | -7.99% |
| 2018 Q4 | 4.5 Billion CNY | -3.96% |
| 2018 Q3 | 4.68 Billion CNY | 11.25% |
| 2018 Q2 | 4.21 Billion CNY | 5.31% |
| 2018 Q1 | 4 Billion CNY | 0.55% |
| 2018 FY | 4.5 Billion CNY | 13.13% |
| 2017 Q1 | 1.89 Billion CNY | 10.85% |
| 2017 Q3 | 2.66 Billion CNY | 17.91% |
| 2017 Q4 | 3.97 Billion CNY | 49.09% |
| 2017 FY | 3.97 Billion CNY | 133.1% |
| 2017 Q2 | 2.26 Billion CNY | 19.62% |
| 2016 Q1 | 1.06 Billion CNY | 4.12% |
| 2016 FY | 1.7 Billion CNY | 66.49% |
| 2016 Q4 | 1.7 Billion CNY | 18.03% |
| 2016 Q3 | 1.44 Billion CNY | 20.4% |
| 2016 Q2 | 1.2 Billion CNY | 12.53% |
| 2015 Q3 | 874.83 Million CNY | 4.86% |
| 2015 FY | 1.02 Billion CNY | 44.3% |
| 2015 Q2 | 834.31 Million CNY | 4.1% |
| 2015 Q4 | 1.02 Billion CNY | 17.21% |
| 2015 Q1 | 801.44 Million CNY | 12.79% |
| 2014 Q3 | 649.42 Million CNY | -4.4% |
| 2014 Q1 | 621.37 Million CNY | 21.04% |
| 2014 FY | 710.58 Million CNY | 38.42% |
| 2014 Q4 | 710.58 Million CNY | 9.42% |
| 2014 Q2 | 679.29 Million CNY | 9.32% |
| 2013 Q3 | 544.12 Million CNY | 23.48% |
| 2013 Q4 | 513.35 Million CNY | -5.65% |
| 2013 Q2 | 440.63 Million CNY | 4.97% |
| 2013 FY | 513.35 Million CNY | 33.1% |
| 2013 Q1 | 419.79 Million CNY | 8.84% |
| 2012 Q4 | 385.69 Million CNY | -6.69% |
| 2012 Q3 | 413.34 Million CNY | 30.29% |
| 2012 Q1 | 302.48 Million CNY | 0.54% |
| 2012 Q2 | 317.25 Million CNY | 4.88% |
| 2012 FY | 385.69 Million CNY | 28.2% |
| 2011 Q3 | 251.4 Million CNY | 21.48% |
| 2011 Q4 | 300.84 Million CNY | 19.67% |
| 2011 Q1 | 192.87 Million CNY | 0.71% |
| 2011 Q2 | 206.94 Million CNY | 7.29% |
| 2011 FY | 300.84 Million CNY | 57.09% |
| 2010 Q4 | 191.51 Million CNY | 0.0% |
| 2010 FY | 191.51 Million CNY | 52.63% |
| 2009 FY | 125.47 Million CNY | 16.23% |
| 2008 FY | 107.95 Million CNY | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| China National Accord Medicines Corporation Ltd. | 7.98 Billion CNY | 85.992% |
| Shenzhen Glory Medical Co.,Ltd. | 371.54 Million CNY | -201.192% |